The Investor Relations website contains information about Tobira Therapeutics business for stockholders, potential investors, and financial analysts.
http://ir.tobiratherapeutics.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
0.9 seconds
PAGES IN
THIS WEBSITE
20
SSL
EXTERNAL LINKS
5
SITE IP
206.200.251.19
LOAD TIME
0.94 sec
SCORE
6.2
Investor Relations - Tobira Therapeutics | ir.tobiratherapeutics.com Reviews
https://ir.tobiratherapeutics.com
The Investor Relations website contains information about Tobira Therapeutics business for stockholders, potential investors, and financial analysts.
ir.tobiratherapeutics.com
Key Ratios - Tobira Therapeutics
http://ir.tobiratherapeutics.com/financials-keyratios.cfm
Data is currently unavailable. 52 Week High $. 52 Week Low $. Average Vol (Mil) (. Market Cap. (Mil). LT Debt/Equity % (. Total Debt/Equity % (. Return on Equity (. Return on Assets (. Return on Investment (. Historical financial information is provided by MorningStar, Inc. Tobira Therapeutics makes no representations or warranties with respect to the information contained herein and takes no responsibility for supplementing, updating, or correcting any such information. 4:00 PM ET on Oct 31, 2016.
Analyst Coverage - Tobira Therapeutics
http://ir.tobiratherapeutics.com/analysts.cfm
Tobira Therapeutics is covered by the following analysts. Elemer Piros, PhD. Please note that any opinions, estimates or forecasts regarding Tobira Therapeutics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Tobira Therapeutics or its management. Tobira Therapeutics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. 4:00 PM ET on Oct 31, 2016.
Management - Tobira Therapeutics
http://ir.tobiratherapeutics.com/management.cfm
Laurent Fischer, M.D. The first treatment approved for Irritable Bowel Syndrome in Europe. Dr. Fischer has co-founded and managed four healthcare companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. Dr. Fischer was responsible for the Global launch of Sustiva. The first once-daily anti-HIV therapy, now part of the fixed dose combination therapy Atripla. And was involved in the launch of Invirase. While at On...
Board of Directors - Tobira Therapeutics
http://ir.tobiratherapeutics.com/directors.cfm
Chairman of the Board. Member of the Nominating and Governance Committee. Carol L. Brosgart, M.D. Carol L. Brosgart, M.D. Member of the Nominating and Governance Committee. Jeffrey H. Cooper. Member of the Audit Committee. Chair of the Nominating and Governance Committee. Laurent Fischer, M.D. Laurent Fischer, M.D.,. Andrew J. Fromkin. Member of the Audit Committee. Chair of the Compensation Committee. Member of the Compensation Committee. Chair of the Audit Committee. Member of the Compensation Committee.
Tobira Therapeutics Reports Second Quarter 2015 Financial Results (NASDAQ:TBRA)
http://ir.tobiratherapeutics.com/releasedetail.cfm?ReleaseID=927176
Aug 11, 2015. File is in Briefcase. Tobira Therapeutics Reports Second Quarter 2015 Financial Results. Positive Momentum on NASH Clinical Program. Strong Quarter-end Cash Position of $63.7 Million. Conference Call to be Held Today at 4:30 pm Eastern Time. SOUTH SAN FRANCISCO, Calif. Aug 11, 2015. Tobira Therapeutics, Inc. MD, Tobira's chief executive officer. Second Quarter 2015 and Recent Business Highlights. Under the ticker symbol TBRA. Completed patient recruitment in the CENTAUR study. CENTAUR i...
TOTAL PAGES IN THIS WEBSITE
20
Investor Relations
Annual Meeting of Stockholders. June 4, 2015 at 8:00 AM CT. Held at the offices of: Fredrikson and Byron. 200 South 6th Street, Suite 4000 - Minneapolis, Minnesota. Primary IR Contact: John Mills, Senior Managing Director john.mills@icrinc.com. Phone: (310) 954-1100 Fax: (310) 954-1101. Sign Up for Investor Relations Alerts. NH - Build and Price - NEW. CIH - Build and Price - NEW. Free Titan Trader Magazine – online or delivered to your home or business.
株主・投資家情報 | 東京個別指導学院
8/17本日発売 週刊エコノミスト に当社社長 齋藤勝己の記事が掲載されました. Benesse サイエンス教室 ４ ５歳児対象 年中生コース の開講月前倒しに関するお知らせ. ファクトブック / 有価証券報告書 / 事業報告書.
INVESTORS
MOEX (RUR): 56.30. Change in % 0.72. Change in % -2.54. Credit ratings and risks. News and IR calendar. TMK Photo Gallery on Flickr. TMK at a glance. TMK Middle East Division. Oil country tubular goods (OCTG). Welded large diameter pipe. Middle East, Asia and Africa. TMK Italia s.r.l. Credit ratings and risks. News and IR calendar. TMK video for investors. TMK securities are traded on the London Stock Exchange, the OTCQX trading platform and Moscow Exchange. Change of the commercial name of TMK. TMK Midd...
T.N. Commerce Bank - Bank on Us!
Bank on the TN Commerce Site Updates. May 14, 2015. Once you’ve browsed and shopped on the TN Commerce Bank site, you’ll discover why you’ll want to return again and again! Money and Finance are areas where just about everyone is looking to do better with these days, and for good reason. The economy is tight we get that! Bank on the TN Commerce Site Updates. Proudly powered by WordPress. By Michael Van Den Berg.
Investor Relations - Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies targeting serious diseases of immune-inflammation and fibrosis. The company’s lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5. CVC is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and has received FastTrack Designation from the FDA. August 17, 2015. August 11, 2015. View all press releases ».
Investor Relations - Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies targeting serious diseases of immune-inflammation and fibrosis. The company’s lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5. CVC is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and has received FastTrack Designation from the FDA. Oct 20, 2016. Oct 19, 2016. Sep 21, 2016 at 2:30 PM PT.
株式会社東栄リーファーライン
The ONE Group Hospitality, Inc. (STKS)
The ONE Group – Lifestyle Hospitality. New York City – Downtown. New York City – Midtown. New York City – Rooftop. New York City – Downtown. New York City – Midtown. New York City – Rooftop. The ONE Group Announces Second Quarter 2015 Results. Aug 13, 2015. STK Owner Mixing Surf and Turf in ‘Transformative’ Deal. STK Rebel Restaurant to Open at Andaz San Diego Hotel. Jun 30, 2015. 2014 Annual Meeting Materials. STKS - Proxy 2014 Annual Meeting. STKS - 2013 Annual Report. Sign up for email alerts. Samuel ...
株主・投資家向情報 - 東邦ホールディングス株式会社
IR情報トップ. 32076;営方針. 26989;績・財務. IRファイリング. 26666;式情報. IRカレンダー. 12522;スク情報. 12469;イトご利用上の注意. 平成27年3月期 決算説明会 2015年5月19日開催 を音声コンテンツにて配信しています。
株主・投資家向け情報 東邦ホールディングス株式会社
IR情報トップ. 32076;営方針. 26989;績・財務. IRファイリング. 26666;式情報. IRカレンダー. 12522;スク情報. 12469;イトご利用上の注意. 平成27年3月期 決算説明会 2015年5月19日開催 を音声コンテンツにて配信しています。
SOCIAL ENGAGEMENT